Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ORMP
CUSIPN/A
Phone011-972-2-566-0001
Debt
Debt-to-Equity RatioN/A
Current Ratio4.19
Quick Ratio4.19
Price-To-Earnings
Trailing P/E Ratio-6.06
Forward P/E Ratio-4.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.46 million
Price / Sales33.80
Cash FlowN/A
Price / CashN/A
Book Value$1.44 per share
Price / Book3.33
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-10,480,000.00
Net Margins-204.00%
Return on Equity-63.20%
Return on Assets-32.64%
Miscellaneous
Employees14
Outstanding Shares17,360,000
Market Cap$84.90 million
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
How were Oramed Pharmaceuticals' earnings last quarter?
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) posted its earnings results on Thursday, July, 12th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.03. The biotechnology company earned $0.62 million during the quarter, compared to analyst estimates of $0.61 million. Oramed Pharmaceuticals had a negative return on equity of 63.20% and a negative net margin of 204.00%. View Oramed Pharmaceuticals' Earnings History.
When is Oramed Pharmaceuticals' next earnings date?
What price target have analysts set for ORMP?
2 analysts have issued 1 year price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 369.7% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.
What is the consensus analysts' recommendation for Oramed Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Synlogic (SYBX), Catalyst Pharmaceuticals (CPRX), Sienna Biopharmaceuticals (SNNA), Concert Pharmaceuticals (CNCE), MEI Pharma (MEIP), Innate Pharma (IPHYF), BIOFRONTERA AG/ADR (BFRA), Paratek Pharmaceuticals (PRTK), Seres Therapeutics (MCRB), Acer Therapeutics (ACER), Aratana Therapeutics (PETX), ProMetic Life Sciences (PFSCF), Axovant Sciences (AXON), Affimed (AFMD) and Tocagen (TOCA).
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Mr. Nadav Kidron Esq., Pres, CEO & Exec. Director (Age 44)
- Mr. Joshua Hexter, COO & VP of Bus. Devel. (Age 48)
- Dr. Miriam Kidron Ph.D., Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 78)
- Ms. Hilla Eisenberg CPA, CFO, Treasurer, Sec. and Principal Financial & Accounting Officer (Age 34)
- Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board
Who are Oramed Pharmaceuticals' major shareholders?
Oramed Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.31%) and BlackRock Inc. (0.16%). Company insiders that own Oramed Pharmaceuticals stock include Aviad Friedman, Miriam Kidron, Nadav Kidron and Xiaopeng Li. View Institutional Ownership Trends for Oramed Pharmaceuticals.
Which major investors are selling Oramed Pharmaceuticals stock?
Which major investors are buying Oramed Pharmaceuticals stock?
ORMP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Aviad Friedman and Xiaopeng Li. View Insider Buying and Selling for Oramed Pharmaceuticals.
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $4.79.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $84.90 million and generates $2.46 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Oramed Pharmaceuticals employs 14 workers across the globe.
What is Oramed Pharmaceuticals' official website?
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 011-972-2-566-0001 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
